Correction to: GLP-1RAs in type 2 diabetes: mechanisms that underlie cardiovascular effects and overview of cardiovascular outcome data

Andrei C Sposito; Otávio Berwanger; Luiz Sérgio F de Carvalho; José Francisco Kerr Saraiva

doi:10.1186/s12933-019-0825-1

Correction to: GLP-1RAs in type 2 diabetes: mechanisms that underlie cardiovascular effects and overview of cardiovascular outcome data

Cardiovasc Diabetol. 2019 Mar 1;18(1):23. doi: 10.1186/s12933-019-0825-1.

Authors

Andrei C Sposito¹, Otávio Berwanger², Luiz Sérgio F de Carvalho³, José Francisco Kerr Saraiva⁴

Affiliations

¹ Atherosclerosis and Vascular Biology Laboratory (AtheroLab), Cardiology Division, Faculty of Medical Sciences, State University of Campinas (Unicamp), Campinas, Sao Paulo, 13084-971, Brazil. andreisposito@gmail.com.
² Academic Research Organization (ARO), Albert Einstein Hospital, Av. Albert Einstein 627, Sao Paulo, SP, 05651-90, Brazil.
³ Atherosclerosis and Vascular Biology Laboratory (AtheroLab), Cardiology Division, Faculty of Medical Sciences, State University of Campinas (Unicamp), Campinas, Sao Paulo, 13084-971, Brazil.
⁴ Cardiology Division, Pontifical Catholic University of Campinas Medicine School, Rua Engenheiro Carlos Stevenson 560, Campinas, Sao Paulo, 13092-132, Brazil.

Abstract

Following publication of the original article [1], based on the authors review, the GLP1 receptor agonists in type 2 diabetes published in Cardiovascular Diabetology, a meta-analysis of GLP-1 and non-GLP-1 based therapies was performed on cardiovascular outcomes.

Publication types

Published Erratum